KR20120110168A - 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법 - Google Patents

종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법 Download PDF

Info

Publication number
KR20120110168A
KR20120110168A KR1020127012981A KR20127012981A KR20120110168A KR 20120110168 A KR20120110168 A KR 20120110168A KR 1020127012981 A KR1020127012981 A KR 1020127012981A KR 20127012981 A KR20127012981 A KR 20127012981A KR 20120110168 A KR20120110168 A KR 20120110168A
Authority
KR
South Korea
Prior art keywords
bcr
antibody
fusion protein
abl
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127012981A
Other languages
English (en)
Korean (ko)
Inventor
샬렛 싱
신준 리우
Original Assignee
프로메테우스 레버러터리스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 레버러터리스 인코포레이티드 filed Critical 프로메테우스 레버러터리스 인코포레이티드
Publication of KR20120110168A publication Critical patent/KR20120110168A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020127012981A 2009-10-20 2010-10-20 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법 Ceased KR20120110168A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25339309P 2009-10-20 2009-10-20
US61/253,393 2009-10-20
US30508410P 2010-02-16 2010-02-16
US61/305,084 2010-02-16
US32748710P 2010-04-23 2010-04-23
US61/327,487 2010-04-23
US38303710P 2010-09-15 2010-09-15
US61/383,037 2010-09-15

Publications (1)

Publication Number Publication Date
KR20120110168A true KR20120110168A (ko) 2012-10-09

Family

ID=43242385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127012981A Ceased KR20120110168A (ko) 2009-10-20 2010-10-20 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법

Country Status (16)

Country Link
US (1) US20120277109A1 (enExample)
EP (1) EP2491385B1 (enExample)
JP (3) JP5819307B2 (enExample)
KR (1) KR20120110168A (enExample)
CN (1) CN102667478B (enExample)
AU (1) AU2010310746B2 (enExample)
BR (1) BR112012009296A2 (enExample)
CA (1) CA2777934A1 (enExample)
DK (1) DK2491385T3 (enExample)
ES (1) ES2637853T3 (enExample)
IL (1) IL219313A (enExample)
MX (1) MX337666B (enExample)
NZ (1) NZ599460A (enExample)
RU (1) RU2558797C2 (enExample)
WO (1) WO2011050069A1 (enExample)
ZA (1) ZA201202957B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120065092A1 (en) * 2010-09-14 2012-03-15 Wai Hobert Fusion analyte cytometric bead assay, and systems and kits for performing the same
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
EP2681552A2 (en) 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
CN102676648A (zh) * 2011-03-07 2012-09-19 重庆医科大学附属儿童医院 白血病诊疗的基因芯片
KR20140020318A (ko) 2011-04-04 2014-02-18 네스텍 소시에테아노님 위암 환자의 생존률 예측 및 개선 방법
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
EP2707723B1 (en) * 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013049398A2 (en) * 2011-09-28 2013-04-04 H. Lee Moffitt Cancer Center & Research Institute, Inc. Protein-protein interaction as biomarkers
US9335292B2 (en) 2011-10-13 2016-05-10 Auburn University Electrochemical proximity assay
EP2788752B1 (en) 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
PL2812024T3 (pl) * 2012-02-09 2018-09-28 Var2 Pharmaceuticals Aps Celowanie glikanów siarczanu chondroityny
ES2678211T3 (es) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
JP2014030572A (ja) * 2012-08-03 2014-02-20 Akira Sakai 抗がん剤投与装置
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
CN103792364B (zh) * 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
HK1218939A1 (zh) 2013-02-05 2017-03-17 Nestec S.A. 用於非小细胞肺癌疗法的药物选择
CN104007257B (zh) * 2013-02-24 2017-02-08 北京莱尔生物医药科技有限公司 一种检测非体液性稀有有核细胞的方法和试剂盒
WO2014141306A2 (en) * 2013-03-15 2014-09-18 Rajiv Gandhi Centre For Biotechnology Methods and materials for identifying therapeutic response in chronic myeloid leukemia
EP3373010A1 (en) 2013-05-21 2018-09-12 Pierian Holdings, Inc. Method for selecting a therapy for the treatment of colorectal cancer patients
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
GB2524519B (en) * 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
WO2016000966A1 (en) * 2014-06-30 2016-01-07 Nestec S.A. Collaborative enzyme enhanced reactive (ceer) immunoassay using flow cytometry
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
US11149299B2 (en) * 2015-06-25 2021-10-19 Ramesh Vallabhaneni Method and system for multiplex profiling of chromosomes in biological samples using target-specific DNA probes
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
WO2018102455A1 (en) * 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
WO2018165566A1 (en) 2017-03-09 2018-09-13 Auburn University Differential circuit for background correction in electrochemical measurements
KR20180117529A (ko) * 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
US11505799B2 (en) 2017-07-07 2022-11-22 Innamed, Inc. Aptamers for measuring lipoprotein levels
US11560565B2 (en) 2018-06-13 2023-01-24 Auburn University Electrochemical detection nanostructure, systems, and uses thereof
CN109439759A (zh) * 2018-12-18 2019-03-08 武汉迪安医学检验实验室有限公司 一种用于检测CBFβ-MYH11融合基因的试剂盒
WO2020140927A1 (en) * 2019-01-02 2020-07-09 Crownmab Biotech Inc. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
AU2021355407A1 (en) 2020-09-29 2023-05-18 Auburn University Dna-based assays
EP4357788A4 (en) 2021-07-13 2025-05-28 Canon Kabushiki Kaisha Method for analyzing specimen, and specimen analyzing device
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本
WO2026036091A1 (en) * 2024-08-09 2026-02-12 Cleancard Inc. Methods, systems and compositions for analyte detection
CN119020510A (zh) * 2024-10-31 2024-11-26 江苏谱新生物医药有限公司 检测k562工程细胞残留的引物探针组合物、试剂盒和方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197199A (en) 1977-10-25 1980-04-08 Manor Engineering Company Limited Filter presses
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
CA2167153A1 (en) 1993-07-15 1995-01-26 Caroline Joy Springer Prodrugs of protein tyrosine kinase inhibitors
WO1995004136A1 (en) * 1993-07-29 1995-02-09 Cor Therapeutics, Inc. Receptor function assays
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6107457A (en) 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
EP0983510B1 (en) * 1997-05-20 2004-03-03 Erasmus Universiteit Rotterdam Recognition of tumour-specific gene products in cancer
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
WO2001029025A2 (en) 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2418105A1 (en) 2000-08-03 2002-02-14 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
US20020132274A1 (en) * 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
US7354773B2 (en) * 2003-05-14 2008-04-08 Beckman Coulter, Inc. Method and apparatus for preparing cell samples for intracellular antigen detection using flow cytometry
EP1507147A1 (en) 2003-08-12 2005-02-16 Erasmus University Medical Center Rotterdam Method for detecting low levels of a fusion protein
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
WO2007061684A1 (en) * 2005-11-18 2007-05-31 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
CN104198705B (zh) * 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
JP2008261764A (ja) * 2007-04-13 2008-10-30 Kyowa Hakko Kogyo Co Ltd キナーゼ阻害物質の測定方法
NZ582618A (en) 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
GB0714573D0 (en) * 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2860247A1 (en) * 2007-08-21 2015-04-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
JP5228416B2 (ja) * 2007-09-12 2013-07-03 株式会社リコー 定電流出力制御型スイッチングレギュレータ
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
EP2108956A1 (en) * 2008-04-07 2009-10-14 Erasmus University Medical Center Rotterdam Improved methods and kits for detecting tumor-specific fusion proteins
US8301258B2 (en) 2008-08-14 2012-10-30 The Chinese University Of Hong Kong Methods and devices for preventing ankle sprain injuries

Also Published As

Publication number Publication date
IL219313A (en) 2017-03-30
RU2012120722A (ru) 2013-11-27
AU2010310746B2 (en) 2015-07-23
ES2637853T3 (es) 2017-10-17
MX2012004619A (es) 2012-05-08
NZ599460A (en) 2014-07-25
CN102667478A (zh) 2012-09-12
IL219313A0 (en) 2012-06-28
CN102667478B (zh) 2018-06-01
US20120277109A1 (en) 2012-11-01
CA2777934A1 (en) 2011-04-28
JP6301892B2 (ja) 2018-03-28
WO2011050069A1 (en) 2011-04-28
DK2491385T3 (en) 2017-08-28
JP2016028251A (ja) 2016-02-25
MX337666B (es) 2016-03-14
EP2491385A1 (en) 2012-08-29
EP2491385B1 (en) 2017-05-10
JP2018119975A (ja) 2018-08-02
AU2010310746A1 (en) 2012-05-03
RU2558797C2 (ru) 2015-08-10
JP2013508728A (ja) 2013-03-07
JP5819307B2 (ja) 2015-11-24
BR112012009296A2 (pt) 2021-02-02
ZA201202957B (en) 2017-01-25

Similar Documents

Publication Publication Date Title
EP2491385B1 (en) Proximity-mediated assays for detecting oncogenic fusion proteins
CN101802618B (zh) 利用基于抗体的阵列选择肺癌治疗药物
CA2716826C (en) Drug selection for breast cancer therapy using antibody-based arrays
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP2751562B1 (en) Profiling of signal pathway proteins to determine therapeutic efficacy
CA2787225A1 (en) Methods for predicting response of triple-negative breast cancer to therapy
US20130324430A1 (en) Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
HK1175529A (en) Proximity-mediated assays for detecting oncogenic fusion proteins
HK1175529B (en) Proximity-mediated assays for detecting oncogenic fusion proteins
HK1185414B (en) Drug selection for breast cancer therapy using antibody-based arrays

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000